10,352 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,352 shares of the company’s stock, valued at approximately $60,000.

Several other institutional investors also recently bought and sold shares of OLMA. Point72 Asset Management L.P. increased its holdings in shares of Olema Pharmaceuticals by 14.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock valued at $44,027,000 after acquiring an additional 475,447 shares during the last quarter. State Street Corp grew its holdings in Olema Pharmaceuticals by 1.1% during the third quarter. State Street Corp now owns 1,969,963 shares of the company’s stock valued at $23,521,000 after purchasing an additional 21,986 shares during the last quarter. Candriam S.C.A. grew its holdings in Olema Pharmaceuticals by 3.0% during the fourth quarter. Candriam S.C.A. now owns 1,551,562 shares of the company’s stock valued at $9,046,000 after purchasing an additional 44,798 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after purchasing an additional 97,428 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Olema Pharmaceuticals by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company’s stock worth $1,941,000 after buying an additional 2,189 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Trading Down 0.3 %

Shares of OLMA stock opened at $3.33 on Thursday. The firm has a market capitalization of $227.55 million, a P/E ratio of -1.52 and a beta of 2.11. Olema Pharmaceuticals, Inc. has a 1 year low of $3.28 and a 1 year high of $16.62. The firm’s fifty day simple moving average is $4.86 and its 200 day simple moving average is $7.87.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.12. Equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Insider Activity at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were purchased at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the purchase, the insider now directly owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on OLMA shares. Oppenheimer reiterated an “outperform” rating and issued a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. Finally, JPMorgan Chase & Co. dropped their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, March 28th.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.